May 15, 2013—Drug manufacturer Mylan has mailed refunds to 340B providers for overcharges on all products sold by its Mylan Specialty subsidiary (formerly known as Dey Pharma) from late 1994 through late 2006.
Last November, the Office of Pharmacy Affairs (OPA) posted a message from Mylan on its home page explaining that the company needed to give refunds to 340B entities due to a recalculation of average manufacturer prices and best prices that Dey Pharma reported to the Centers for Medicare and Medicaid Services (CMS) under the Medicaid rebate program.[ms-protect-content id=”2799″] Mylan bought Dey Pharma in 2007 and renamed it Mylan Specialty in February 2012.
The Mylan 340B refunds cover all products bearing NDC labeler code 495021 from the third quarter of 1994 through the fourth quarter of 2006. Past and present Dey Pharma/Mylan Specialty products with relatively high rates of utilization include the EpiPen and EpiPen Jr epinephrine auto-injectors as well as albuterol and albuterol/ipratropium nebulizer solutions.
Providers with questions about the refunds should contact Mylan Manager of Government Pricing & Reporting Terry Pierce by telephone at (304) 554-5256 or by fax at (304) 553-6853.[/ms-protect-content]